Team Inc. Grows Revenue on IHT but Faces GAAP Losses, High Debt and AR Cash Strain

Team, Inc. (NYSE: TISI)

Quick read: Team reported solid top-line growth driven by Inspection & Heat Treating (IHT), but GAAP earnings are under pressure from heavy interest, refinancing costs and working-capital cash drain. Management completed a March 12, 2025 refinancing (First Lien + Second Lien), is current on covenants, and carries a material legal accrual largely covered by insurance - however liquidity and leverage remain the main risks.

What's happening inside the company
- Management pushed a refinancing on March 12, 2025: Initial First Lien Term Loan drawn ($175.0M) and 2025 Second Lien Term Loans established; proceeds used to repay several Corre and ME/RE facilities and to reorganize debt. This reduced some onerous facilities but generated an $11.853M loss on debt extinguishment (non‑cash portion included).
- Business mix shift: IHT is growing fast (turnarounds and callouts in U.S. & Canada) while Mechanical Services (MS) activity cooled in certain international markets that had one‑time 2024 shutdowns. Management is emphasizing field cost rationalization in IHT.
- Working capital pressure: accounts receivable and unbilled revenue increased materially (total AR $207,533k), driving a large cash outflow from operations for the six months ended 6/30/2025.
- Legal: $39.0M accrual for the Kelli Most matter is recorded and matched by an insurance receivable of the same amount; total legal/contingent accruals ≈ $40.7M (only ~$1.7M uninsured). Timing and final outcome still uncertain.
- Covenants & liquidity: Company reports being in compliance with covenants as of 6/30/2025 and had available borrowing capacity (~$32.7M) under facilities; management states liquidity sufficient for next 12 months based on forecasts, but actual results depend on collections and market conditions.
Positive aspects of the income statement / financials
- Revenue growth: Q2 2025 revenues $248,026k vs Q2 2024 $228,618k (+8.5%); six months $446,681k vs $428,218k (+4.3%).
- Segment strength: IHT revenue up sharply - Q2 IHT $130,396k (+15.2% YoY); six months IHT $236,611k (+11.3% YoY). IHT adjusted EBITDA up (Q2 IHT adjusted EBITDA $19,490k vs $15,589k prior year).
- Improved adjusted operating performance: Consolidated adjusted EBITDA Q2 2025 $24,471k (vs $21,813k Q2 2024); six months $29,781k vs $28,320k - showing core cash‑generation potential before financing, D&A and working capital.
- Operating income up: Operating income Q2 2025 $12,103k vs $11,159k prior year; operating income excluding identified non‑core items rose to $15,578k (Q2).
Negative aspects of the income statement / financials
- GAAP losses: Net loss Q2 2025 $(4,266)k vs $(2,763)k prior year; six‑month net loss $(33,984)k vs $(19,958)k - materially worse YTD.
- Heavy finance costs and debt-related charges: Interest expense remains substantial (net interest Q2 $(11,896)k; six months $(23,332)k). PIK interest is being capitalized on certain debt and increased effective cost on second lien (PIK added $4,183k to principal).
- One‑time refinancing hit: Loss on debt extinguishment $(11,853)k in six months (non‑core but material to GAAP results).
- Cash flow weakness: Net cash used in operating activities for six months $(32,005)k; Free cash flow six months $(36,321)k (operating cash − capex), driven by a large increase in AR/unbilled balances.
- Balance sheet stress: Total liabilities $571,285k > total assets $548,361k; shareholders' equity (deficit) $(22,924)k as of 6/30/2025. Total long‑term debt & finance leases net carrying ~$366,381k (long‑term portion).
- FX and other items: Foreign currency losses hit other expense (Q2 other expense $(3,490)k). Also increased professional/legal non‑core costs pressured corporate expense.
Key numbers & facts (as reported, in thousands unless noted)
- Revenues Q2 2025: $248,026; Six months: $446,681.
- Gross margin Q2: $68,089; Operating income Q2: $12,103.
- Net loss Q2: $(4,266); Six months: $(33,984).
- Loss per share - basic & diluted Q2: $(0.95); Six months: $(7.56).
- Adjusted EBITDA Q2: $24,471; Six months: $29,781.
- Cash & cash equivalents 6/30/2025: $20,709 (restricted cash $4,100 of that); cash 12/31/2024: $35,545.
- AR (net) 6/30/2025: $207,533 (unbilled revenue $48,946).
- Inventory 6/30/2025: $41,539.
- Total assets: $548,361; Total liabilities: $571,285; Shareholders' equity (deficit): $(22,924).
- Total long‑term debt & finance lease obligations (less current portion): $366,381; total long‑term debt + finance leases: $370,214.
- Revolving credit principal 6/30/2025: $97,886; Initial First Lien principal balance ~$174,563 (net carrying $166,474).
- 2025 Second Lien principal balance: $101,376 (net carrying $98,065); PIK interest added $4,183 during period.
- Available borrowing capacity 6/30/2025: ~$32.7M (Revolver $22.7M + Second Lien delayed draw $10M).
- Letters of credit outstanding: ~$30.5M; Substitute insurance letters of credit: $19.0M.
- Legal accruals / contingencies: total accruals ≈ $40.7M; Kelli Most accrual $39.0M matched by $39.0M insurance receivable; uninsured exposure ≈ $1.7M.
- Shares outstanding (Aug 8, 2025): 4,498,854.

Bottom line: core operations (especially IHT) are growing and adjusted EBITDA improved, but GAAP profitability is negative, cash from operations is weak, leverage remains high after refinancing, and legal & working‑capital risks are material. Investors should watch AR collections, actual cash interest outflows vs PIK, covenant tests each quarter, and the resolution/timing of insurance recoveries tied to the big litigation accrual.

If you want, I can produce a 12‑month cash‑flow sensitivity (best/worst cases) and scenario showing covenant headroom under different AR collection assumptions.